Good response to pentamidine isethionate in a case of Mucosal Leishmaniasis caused by Leishmania (Viannia) braziliensis that was difficult to treat: Case Report.

Autor:	Ferreira Terceiro BR; Instituto Nacional de Infectologia, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brasil., Torraca TSS; Departamento de Otorrinolaringologia e Oftalmologia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil., Braga FPB; Instituto Nacional de Infectologia, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brasil., Martins ACDC; Instituto Nacional de Infectologia, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brasil., Brahim LR; Instituto Nacional de Infectologia, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brasil., Saheki MN; Instituto Nacional de Infectologia, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brasil., Miranda LFC; Instituto Nacional de Infectologia, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brasil., Schubach AO; Instituto Nacional de Infectologia, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brasil., Valete-Rosalino CM; Instituto Nacional de Infectologia, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brasil.; Departamento de Otorrinolaringologia e Oftalmologia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil.
Jazyk:	angličtina
Zdroj:	Revista da Sociedade Brasileira de Medicina Tropical [Rev Soc Bras Med Trop] 2019 Jan 17; Vol. 52, pp. e20180236. Date of Electronic Publication: 2019 Jan 17.
DOI:	10.1590/0037-8682-0236-2018
Abstrakt:	In Brazil, meglumine antimoniate is the first drug of choice for mucosal leishmaniasis treatment followed by amphotericin B and pentamidine isethionate. We report the case of a patient with severe mucosal lesions caused by Leishmania (Viannia) braziliensis that were difficult to treat. Over a 14-year period, the patient showed low adherence and three treatment attempts with meglumine antimoniate failed. Additionally, there was an unsatisfactory response to liposomal amphotericin B and nephrotoxicity when using amphotericin B deoxycholate that persisted after new treatment attempt with liposomal amphotericin B. Finally, healing was achieved with pentamidine isethionate and maintained during nine months of monitoring.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu